PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first.
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival.
Canva; Everyday Health
The annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research meetings of its kind, bringing together a range of researchers, from those who spend their time in the lab to those who focus on patients in the clinic. The meeting atmosphere is electric even when it’s virtual. Here are five key studies that stood out during the first week of the virtual AACR meeting, held April 10–15, 2021.
Lymphoma Progression Cut in Half When Rituxan Is Paired With Aliqopa
What’s new Patients with relapsed indolent non-Hodgkin lymphoma saw a 48 percent reduced risk of progression (time without the disease advancing or death) when the targeted therapy Aliqopa (copanlisib) was used in combination with Rituxan (rituximab) versus Rituxan alone. Rituxan alone is the current standard therapy for relapses. The results, which come from a phase 3 trial known as CHRONOS-3, were announced at the AACR meeting and simultaneously p
Tebentafusp improves OS: A First in Metastatic Uveal Melanoma medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.